Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABSI NASDAQ:CRTO NASDAQ:NUTX NASDAQ:OABI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABSIAbsci$4.64-6.3%$3.72$2.24▼$6.72$770.95M2.365.55 million shs4.59 million shsCRTOCriteo$17.14+5.7%$18.02$15.57▼$28.11$808.22M0.34340,179 shs449,260 shsNUTXNutex Health$126.39+1.4%$107.37$77.21▼$193.07$858.10M0.25167,379 shs87,209 shsOABIOmniAb$2.37+3.5%$1.67$1.22▼$2.46$331.55M0.07963,396 shs1.19 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABSIAbsci-3.51%-14.36%+38.27%+86.09%+71.88%CRTOCriteo+0.93%+0.62%-16.79%-4.93%-42.96%NUTXNutex Health-1.27%-6.16%+18.11%+23.06%-28.62%OABIOmniAb+5.05%+37.13%+39.63%+33.92%+44.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABSIAbsci$4.64-6.3%$3.72$2.24▼$6.72$770.95M2.365.55 million shs4.59 million shsCRTOCriteo$17.14+5.7%$18.02$15.57▼$28.11$808.22M0.34340,179 shs449,260 shsNUTXNutex Health$126.39+1.4%$107.37$77.21▼$193.07$858.10M0.25167,379 shs87,209 shsOABIOmniAb$2.37+3.5%$1.67$1.22▼$2.46$331.55M0.07963,396 shs1.19 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABSIAbsci-3.51%-14.36%+38.27%+86.09%+71.88%CRTOCriteo+0.93%+0.62%-16.79%-4.93%-42.96%NUTXNutex Health-1.27%-6.16%+18.11%+23.06%-28.62%OABIOmniAb+5.05%+37.13%+39.63%+33.92%+44.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABSIAbsci 2.50Moderate Buy$7.5362.28% UpsideCRTOCriteo 2.44Hold$27.9463.04% UpsideNUTXNutex Health 2.50Moderate Buy$205.0062.20% UpsideOABIOmniAb 2.33Hold$3.0026.58% UpsideCurrent Analyst Ratings BreakdownLatest OABI, NUTX, ABSI, and CRTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026ABSIAbsci Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.105/13/2026CRTOCriteo Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$33.00 ➝ $29.005/8/2026ABSIAbsci Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.005/7/2026CRTOCriteo BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $25.005/6/2026CRTOCriteo Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$34.00 ➝ $18.005/6/2026CRTOCriteo Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight5/4/2026NUTXNutex Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/4/2026OABIOmniAb Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/29/2026CRTOCriteo Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$35.00 ➝ $34.004/20/2026ABSIAbsci Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CRTOCriteo Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABSIAbsci$2.80M258.18N/AN/A$1.10 per share4.22CRTOCriteo$1.94B0.44$6.83 per share2.51$23.45 per share0.73NUTXNutex Health$875.26M0.99$13.08 per share9.66$64.24 per share1.97OABIOmniAb$18.67M18.38N/AN/A$1.81 per share1.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABSIAbsci-$115.18M-$0.83N/AN/AN/A-6,450.76%-66.32%-57.01%N/ACRTOCriteo$144.60M$2.148.014.91N/A6.06%14.98%8.25%8/5/2026 (Estimated)NUTXNutex Health$70.79M$12.949.77N/AN/A10.95%23.50%10.47%7/30/2026 (Estimated)OABIOmniAb-$64.78M-$0.46N/AN/AN/A-187.59%-20.31%-18.10%8/6/2026 (Estimated)Latest OABI, NUTX, ABSI, and CRTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ABSIAbsci-$0.20-$0.19+$0.01-$0.19$1.39 million$0.22 million5/7/2026Q1 2026OABIOmniAb-$0.10-$0.06+$0.04-$0.06$5.60 million$14.43 million5/6/2026Q1 2026CRTOCriteo$0.57$0.73+$0.16$0.15$248.21 million$424.64 million4/30/2026Q1 2026NUTXNutex Health$3.99$6.52+$2.53$6.52$227.80 million$216.49 million3/31/2026Q1 2026CRTOCriteoN/A$0.73N/A$0.15N/A$424.64 million3/24/2026Q4 2025ABSIAbsci-$0.16-$0.23-$0.07-$0.20$1.38 million$0.65 million3/5/2026Q4 2025NUTXNutex Health$5.56$1.61-$3.95$1.61$258.82 million$151.68 million3/4/2026Q4 2025OABIOmniAb-$0.08-$0.11-$0.03-$0.11$9.00 million$8.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABSIAbsciN/AN/AN/AN/AN/ACRTOCriteoN/AN/AN/AN/AN/ANUTXNutex HealthN/AN/AN/AN/AN/AOABIOmniAbN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABSIAbsciN/A6.596.59CRTOCriteoN/A1.281.28NUTXNutex Health0.663.143.12OABIOmniAbN/A4.804.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABSIAbsci52.05%CRTOCriteo94.27%NUTXNutex Health5.32%OABIOmniAb72.08%Insider OwnershipCompanyInsider OwnershipABSIAbsci10.49%CRTOCriteo1.52%NUTXNutex Health44.68%OABIOmniAb9.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABSIAbsci210155.90 million139.55 millionOptionableCRTOCriteo3,64949.86 million49.10 millionOptionableNUTXNutex Health1,1506.88 million3.81 millionNot OptionableOABIOmniAb7144.78 million130.59 millionOptionableOABI, NUTX, ABSI, and CRTO HeadlinesRecent News About These CompaniesOmniAb Stock Price HistoryMay 13, 2026 | investing.comOmniAb (NASDAQ:OABI) Issues Earnings ResultsMay 9, 2026 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: OmniAb (OABI), Gilead Sciences (GILD)May 9, 2026 | theglobeandmail.comOmniAb (OABI) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comOmniAb Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comOmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2026 | zacks.comOmniAb Inc (OABI) Q1 2026 Earnings Report Preview: What To ExpectMay 7, 2026 | finance.yahoo.comOmniAb Reports First Quarter 2026 Financial Results and Business HighlightsMay 7, 2026 | businesswire.comOmniAb (OABI) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comOmniAb (NASDAQ:OABI) Shares Down 2.8% - Here's What HappenedApril 29, 2026 | marketbeat.comBullish OmniAb Insiders Loaded Up On US$1.28m Of StockApril 22, 2026 | finance.yahoo.comOmniAb (OABI) well-positioned for momentum build-up in 2026April 14, 2026 | msn.comInsider Selling: OmniAb (NASDAQ:OABI) CFO Sells 6,913 Shares of StockApril 8, 2026 | insidertrades.comHere is why you should not ignore OmniAb Inc. (OABI)March 31, 2026 | msn.comOmniAb (OABI) Q4 2025 Earnings Call TranscriptMarch 15, 2026 | finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Q4 2025 earnings call transcriptMarch 6, 2026 | msn.comOmniAb, Inc. (OABI) Q4 2025 Earnings Call TranscriptMarch 5, 2026 | seekingalpha.comOmniAb Inc (OABI) Q4 2025 Earnings Call Highlights: Strong Partner Engagement and New ...March 5, 2026 | uk.finance.yahoo.comOmniAb outlines $25M–$30M 2026 revenue guidance as partner pipeline accelerates with OmniUltra and xPloration launchesMarch 5, 2026 | seekingalpha.comOmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue EstimatesMarch 4, 2026 | zacks.comOmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsMarch 4, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOABI, NUTX, ABSI, and CRTO Company DescriptionsAbsci NASDAQ:ABSI$4.64 -0.31 (-6.32%) Closing price 03:59 PM EasternExtended Trading$4.70 +0.06 (+1.34%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.Criteo NASDAQ:CRTO$17.14 +0.93 (+5.74%) Closing price 04:00 PM EasternExtended Trading$17.02 -0.12 (-0.70%) As of 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Criteo S.A., a technology company, provides marketing and monetization services on the open Internet in North and South America, Europe, the Middle East, Africa, and the Asia-Pacific. The company's Criteo Shopper Graph, which derives clients' proprietary commerce data, such as transaction activity on their digital properties. It also offers Criteo AI Engine solutions, including lookalike finder, recommendation, and predictive bidding algorithms; recommendation algorithms, dynamic creative optimization+, sponsored product placement algorithms, and other product placement algorithms. The company's technology comprises data synchronization, storage, and analysis of distributed computing infrastructure in various geographies, as well as fast data collection and retrieval using multi-layered caching infrastructure; and experimentation platform, an offline/online testing platform to enhance the capabilities and effectiveness of prediction models. In addition, it provides Criteo Marketing Solutions that allow commerce companies to address various marketing goals by engaging their consumers with personalized ads across the web, mobile, and offline store environments; and Criteo Retail Media solutions, which allows retailers to generate advertising revenues from consumer brands, and/or to drive sales for themselves, by monetizing their data and audiences through personalized ads, either on their own digital property or on the open Internet. Further, the company offers real-time advertising technology and trading infrastructure, delivering advanced media buying, selling, and packaging capabilities for media owners, agencies, performance advertisers, and third-party AdTech platforms. It serves companies in digital retail, travel, and classifieds sectors. Criteo S.A. was incorporated in 2005 and is headquartered in Paris, France.Nutex Health NASDAQ:NUTX$126.39 +1.69 (+1.36%) Closing price 04:00 PM EasternExtended Trading$126.24 -0.16 (-0.12%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nutex Health Inc. operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management. The Real Estate segment owns and owns and leases land and hospital building. The Hospital segment develops and operates a network of micro-hospitals, specialty hospitals and hospital outpatient departments which offers 24/7 care. It also provides operational and managerial services, including management, billing, collections, human resources and recruiting, legal, accounting, and marketing. In addition, the company offers healthcare services, including emergency room care, inpatient care, and behavioral health, as well as onsite imaging, such as CT scan, X-ray, MRI, ultrasound, etc.; certified and accredited laboratories; and onsite inpatient pharmacies. The company was founded in 2011 and is based in Houston, Texas.OmniAb NASDAQ:OABI$2.37 +0.08 (+3.49%) Closing price 04:00 PM EasternExtended Trading$2.40 +0.03 (+1.10%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
